Mechanisms and Clinical Effects of Rituximab and its Multifaceted Comparison with Biosimilars
DOI:
https://doi.org/10.61173/zbf98707Keywords:
Rituximab, CD20, Truxima, signaling pathways, clinical trialsAbstract
Rituximab, targeting CD20, is one of the first-line treatments against Diffuse Large B-cell lymphoma (DLBCL), Follicular Lymphoma, Lymphoplasmacytic Lymphoma (LPL), and other B cell mutations. As the patent on Rituximab expires and a large number of biosimilars are on the market, Rituximab is an important milestone in the era of immunotherapy as the first monoclonal antibody to be approved for oncology treatment. The mechanisms of its anticancer effects include Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Antibody-Dependent Phagocytosis (ADCP), direct signaling-induced cell death, etc. The biosimilar Truxima, which is now used worldwide, is also tending to surpass it by the expiration of the original Rituximab patent. This paper focuses on the working principle and clinical effects of Rituximab, the characteristics and pathway principles of the drug target CD20, as well as the physical and chemical properties of reference drugs and biosimilars. This review also summarizes the importance of monoclonal antibody technologies such as Rituximab and CD20 antibodies in the treatment of related cancers. Further studies are required for clinical applications of Truxima as a substitute for Rituximab.
References
[1] Pavlasova G, Mraz M. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica, 2020, 105(6): 1494-1506.
[2] Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers are physically associated with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem, 2008, 283(27): 18545- 18552.
[3] Butler LA, Tam CS, Seymour JF. Dancing partners at the ball: rational selection of next-generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agent’s era. Blood, Rev, 2017, 31(5): 318–27.
[4] Lionel Rougé et al., Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science, 2020, 367, 12224-1230.
[5] Unruh TL, Li H, Mutch CM, Shariat N, Grigoriou L, Sanyal R, et al. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology, 2005, 116:223-32.
[6] Stadlbauer K, Andorfer P, Stadlmayr G, Rüker F, Wozniak- Knopp G. Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab. Int J Mol Sci, 2022, 23(9): 5208.
[7] Beers SH, Cragg MS, Glennie MJ. Complement: help or hindrance? Blood, 2009, 114: 5567-8.
[8] Boross P, Leusen JHW. Mechanisms of action of CD20 antibodies. Am J Cancer Res, 2012, 2: 676–90.
[9] Juárez-Salcedo LM, Conde-Royo D, Quiroz-Cervantes K, Dalia S. Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. Drugs Context, 2020, 9:2019-9-3.
[10] Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys, 2012, 526: 146–53.
[11] LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[12] Suzhou Institute of Nano Tech and Nano Bionics of CAS.A mass spectrometry analysis method for pharmacokinetic studies of rituximab: CN111239273A [P]. 2020-06-05[2024-2-20].
[13] Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs, 2013, 27(5): 495-507.
[14] Chung S, Quarmby V, Gao X, et al. Quantitative evaluation of fucose-reducing effects in a humanized antibody on Fc receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs, 2012, 4(3): 326-40.
[15] Greenwald M, Tesser J, Sewell KL. Biosimilars Have Arrived: Rituximab. Arthritis, 2018, 2018: 3762864.
[16] Yoo DH, Suh CH, Shim SC, Lee SJ, Kim SH, Park W. A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol, 2020, 16(12): 1125-1132.
[17] McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol, 1998, 16: 2825–33.
[18] Levin J, Summit N., US Food and Drug Administration Approves REVLIMID® (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma(Jun 5, 2013), Available online at: https://www. fiercebiotech.com/biotech/u-s-food-and-drug-administrationapproves-revlimid%C2%AE-lenalidomide-for-treatment-ofpatients
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
